| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| nilotinib fda label 2023 | 1.37 | 0.2 | 7448 | 69 | 24 |
| nilotinib | 1.33 | 0.8 | 4079 | 34 | 9 |
| fda | 1.86 | 0.1 | 5772 | 99 | 3 |
| label | 0.81 | 0.4 | 4947 | 26 | 5 |
| 2023 | 0.21 | 0.1 | 7394 | 85 | 4 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| nilotinib fda label 2023 | 1.74 | 0.3 | 6092 | 49 |
| nivolumab fda label 2023 | 0.47 | 1 | 9859 | 95 |
| nilotinib phase 3 trial | 0.44 | 0.3 | 4809 | 24 |
| nivolumab fda label 2022 | 1.16 | 0.5 | 1151 | 79 |
| rinvoq fda label 2023 | 1.23 | 0.7 | 6503 | 16 |
| nilotinib hydrochloride usp monograph | 1.32 | 0.9 | 272 | 47 |
| nilotinib_1013 | 1.41 | 0.9 | 1844 | 39 |
| anlotinib fda approval history | 0.86 | 0.9 | 292 | 54 |
| dupilumab fda label 2023 | 1.81 | 0.9 | 6152 | 43 |
| nilotinib structure based drug design | 2 | 0.6 | 6902 | 4 |
| nivolumab prescribing information 2023 | 1.66 | 0.2 | 6418 | 22 |
| nilotinib brands in india | 1.22 | 0.4 | 2434 | 41 |
| erlotinib fda approval history | 0.22 | 0.1 | 6241 | 50 |
